Hunan Cancer Hospital — Changsha, Hunan

Public research footprint of Hunan Cancer Hospital, compiled from the ClinicalTrials.gov public registry.

778

Registered studies

431

Active

250

Recruiting now

172

Completed

Stopped or withdrawn

Most-studied conditions

Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer · Breast Neoplasms · Relapsed/Refractory Follicular Lymphoma · Hepatocellular Carcinoma

Recently updated registry entries

NCT06952504 — A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… (Recruiting)
NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… (Recruiting)
NCT06841354 — A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hunan Cancer Hospital?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 03, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.